MET:NYSEMetLife, Inc. Analysis

MetLife (MET) is trading at $85.76, comfortably above its 20‑day ($84.61), 50‑day ($80.81) and 200‑day ($78.18) simple moving averages, indicating a bullish price action. The RSI sits at 58.5, suggesting modest upward momentum, while the MACD histogram is slightly negative and the signal line is flagged as bearish, hinting at a near‑term pause. The stock respects a clear support zone around $80.51 and faces resistance near $89.62, with a 30‑day volatility of 21.4% and a beta of 0.88, pointing to higher price swings but lower market‑wide risk.
Fundamentally, MET trades at a trailing PE of 16.6 versus an industry average of 16.9 and a forward PE of 7.8, implying significant earnings upside. The dividend yield of 2.71% with a 44% payout ratio appears sustainable given solid operating cash flow, though free cash flow is negative and the debt‑to‑equity ratio is high at 178%. A DCF model values the company near $218, suggesting a modest upside of about 7% from current levels, while recent product launches and analyst upgrades (Morgan Stanley, Piper Sandler) provide fresh positive catalysts.